Measurement and determinants of tuberculosis outcome in Karonga District, Malawi

Bulletin of the World Health Organization

Volumn 76, Issue 3, 1998, Pages 295-305

  Glynn, J R ^a   Warndorff, D K ^b   Fine, P E M ^a   Munthali, M M ^a   Sichone, W ^b   Ponnighaus J M ^b,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KARONGA PREVENTION STUDY   (Malawi)

^c Hautklinik Plauen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

DISEASE PREVALENCE; MONITORING; RURAL POPULATION; TUBERCULOSIS;

ADULT; ARTICLE; DISEASE CONTROL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK ASSESSMENT; RISK FACTOR; RURAL AREA; SMEAR; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; AFRICA SOUTH OF THE SAHARA; DEATH RATE; DEMOGRAPHIC FACTORS; DEVELOPING COUNTRIES; DISEASES; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; HIV INFECTIONS; INFECTIONS; MALAWI; MEASUREMENT; MORTALITY; ORGANIZATION AND ADMINISTRATION; POPULATION; POPULATION DYNAMICS; PROGRAM EVALUATION; PROGRAMS; RESEARCH METHODOLOGY; RESEARCH REPORT; SAMPLING STUDIES; STUDIES; SURVEYS; TREATMENT; TUBERCULOSIS; VIRAL DISEASES;

ADULT; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; MALAWI; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUBERCULOSIS;

MALAWI;

EID: 0031826556     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle, 1991, 72: 1-6.
2. Harries AD et al. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Lancet, 1996, 347: 807-809.
3. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis. Lancet, 1996, 347: 358-362.
4. Enarson DA et al. Tuberculosis guide for low income countries, 3rd edit. Paris, International Union against Tuberculosis and Lung Disease, 1994.
5. Murray CJL et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet, 1991, 338: 1305-1308.
6. Pönnighaus JM et al. The Lepra Evaluation Project (LEP) an epidemiological study of leprosy in northern Malawi. I: methods. Leprosy review, 1987, 58: 359-375.
7. Pönnighaus JM et al. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malawi - I: methods of the vaccination phase. Leprosy review, 1993, 64: 338-356.
8. Sterne JAC et al. Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. Journal of infectious diseases, 1995, 172: 543-546.
9. Glynn JR et al. Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. Lancet, 1995, 345: 907-910.
10. Nyangulu DS. The point of view of a high prevalence country: Malawi. Bulletin of the International Union against Tuberculosis and Lung Disease, 1991, 66: 173-174.
11. Fine PEM et al. The distribution and implications of BCG scars in northern Malawi. Bulletin of the World Health Organization, 1989, 67: 35-42.
12. East African/British Medical Research Council. Tuberculosis in Kenya: follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey. Tubercle, 1979, 60: 125-149.
13. East African/British Medical Research Council. Tuberculosis in Kenya: a follow-up of a national sampling survey of drug resistance and other factors. Tubercle, 1970, 51: 1-23.
14. Perriens JH et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. American review of respiratory disease, 1991, 144: 750-755.
15. Nunn P et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. American review of respiratory disease, 1992, 146: 849-854.
16. Elliott AM et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89: 78-92.
17. Ackah AN et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet, 1995, 345: 607-609.
18. Pönnighaus JM et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet, 1992, 339: 636-639.
19. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, 1996, 348: 17-24.
20. Colebunders RL et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. American review of respiratory disease, 1989, 139: 1082-1085.
21. Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle and lung disease, 1996, 77: 124-129.
22. Hawken M et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet, 1993, 342: 332-337.
23. Elliott AM et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. Journal of tropical medicine and hygiene, 1995, 98: 9-21.
24. Ringdal T, Veen J. Report on a visit to Malawi. Progress Report No. 23. Paris International Union against Tuberculosis and Lung Disease, 1995 (unpublished document).